Trial Profile
Evaluation of Gadoterate in Patients With Renal Dysfunction
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2021
Price :
$35
*
At a glance
- Drugs Gadoterate-meglumine (Primary)
- Indications Kidney disorders
- Focus Diagnostic use
- 05 Jun 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Oct 2019.
- 05 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.